What is CorMedix's return on equity?

CorMedix (CRMD) reported return on equity of 65.6% in Q1 2026.

What is the long-term trend for CorMedix's return on equity?

Over 4 years (2020 to 2025), CorMedix's return on equity has grown at a 0.6% compound annual growth rate (CAGR), from -64.9% to 66.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

CorMedix CRMD Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

Merck & Co.MRK

19%-20.3pp

Merit Medical SystemsMMSI

9.1%0.0pp

ITG

Integer HoldingsITGR

8.6%+3.7pp

IAR

Integra LifeSciencesIART

-38.6%—

MiMedx GroupMDXG

13.8%-8.6pp

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

net income/total stockholders equity=65.6%

Based on trailing twelve months.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's return on equity?: CorMedix (CRMD) reported return on equity of 65.6% in Q1 2026.
What is the long-term trend for CorMedix's return on equity?: Over 4 years (2020 to 2025), CorMedix's return on equity has grown at a 0.6% compound annual growth rate (CAGR), from -64.9% to 66.6%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.